119 related articles for article (PubMed ID: 29855051)
1. Changes in clinical stage identify patients with CLL and different outcome within iwCLL partial response: RESONATE study.
Moreno C; Delgado J; Byrd JC; Zvagelsky WL; Suzuki S; Hsu E; James DF; Montserrat E
Br J Haematol; 2019 Apr; 185(1):148-150. PubMed ID: 29855051
[No Abstract] [Full Text] [Related]
2. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C?
Visco C; Cortelezzi A; Moretta F; Falisi E; Maura F; Finotto S; Barcellini W; Ambrosetti A; Neri A; Ruggeri M; Rodeghiero F
Leuk Lymphoma; 2014 Jun; 55(6):1261-5. PubMed ID: 24047107
[TBL] [Abstract][Full Text] [Related]
4. In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI.
Rigolin GM; Cavallari M; Quaglia FM; Formigaro L; Lista E; Urso A; Guardalben E; Liberatore C; Faraci D; Saccenti E; Bassi C; Lupini L; Bardi MA; Volta E; Tammiso E; Melandri A; Negrini M; Cavazzini F; Cuneo A
Blood; 2017 Jun; 129(26):3495-3498. PubMed ID: 28446433
[No Abstract] [Full Text] [Related]
5. Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia.
Perbellini O; Falisi E; Giaretta I; Boscaro E; Novella E; Facco M; Fortuna S; Finotto S; Amati E; Maniscalco F; Montaldi A; Alghisi A; Aprili F; Bonaldi L; Paolini R; Scupoli MT; Trentin L; Ambrosetti A; Semenzato G; Pizzolo G; Rodeghiero F; Visco C
Haematologica; 2014 May; 99(5):881-7. PubMed ID: 24415628
[TBL] [Abstract][Full Text] [Related]
6. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
Valgañón M; Giraldo P; Agirre X; Larráyoz MJ; Rubio-Martinez A; Rubio-Felix D; Calasanz MJ; Odero MD
Br J Haematol; 2005 Apr; 129(1):53-9. PubMed ID: 15801955
[TBL] [Abstract][Full Text] [Related]
7. Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and Are Surrogates for Response to Therapy.
Vicente EP; Cuellar-García C; Martinez M; Soler A; Mora A; Bosch R; Brunet S; Briones J; García I; Esquirol A; Granell M; Saavedra S; Nomdedeu J; Sierra J; Martino R; Moreno C
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):737-742. PubMed ID: 30017595
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.
Mato A; Nabhan C; Kay NE; Lamanna N; Kipps TJ; Grinblatt DL; Flowers CR; Farber CM; Davids MS; Kiselev P; Swern AS; Bhushan S; Sullivan K; Flick ED; Sharman JP
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):114-124.e2. PubMed ID: 29352719
[TBL] [Abstract][Full Text] [Related]
9. Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the 2008 International Workshop on CLL guidelines.
Molica S; Giannarelli D; Mirabelli R; Levato L; Gentile M; Lentini M; Morabito F
Expert Rev Hematol; 2014 Oct; 7(5):691-5. PubMed ID: 25174547
[TBL] [Abstract][Full Text] [Related]
10. Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial.
Scheffold A; Jebaraj BMC; Jaramillo S; Tausch E; Steinbrecher D; Hahn M; Böttcher S; Ritgen M; Bunjes D; Zeis M; Stadler M; Uharek L; Scheid C; Hegenbart U; Hallek M; Kneba M; Schmitz N; Döhner H; Dreger P; Stilgenbauer S
Br J Haematol; 2017 Oct; 179(2):342-346. PubMed ID: 27391907
[No Abstract] [Full Text] [Related]
11. Prognostic factors in chronic lymphocytic leukaemia.
Binet JL
Haematologica; 1999 Jun; 84 Suppl EHA-4():96-7. PubMed ID: 10907482
[No Abstract] [Full Text] [Related]
12. Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL.
Heyman B; Volkheimer AD; Weinberg JB
Blood Cancer J; 2016 Jul; 6(7):e440. PubMed ID: 27367477
[No Abstract] [Full Text] [Related]
13. Elevated miR-20b-5p expression in peripheral blood mononuclear cells: A novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia.
Papageorgiou SG; Kontos CK; Tsiakanikas P; Stavroulaki G; Bouchla A; Vasilatou D; Bazani E; Lazarakou A; Scorilas A; Pappa V
Leuk Res; 2018 Jul; 70():1-7. PubMed ID: 29715621
[TBL] [Abstract][Full Text] [Related]
14. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K
Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689
[TBL] [Abstract][Full Text] [Related]
15. Prognostic markers in chronic lymphocytic leukaemia.
Hamblin TJ
Best Pract Res Clin Haematol; 2007 Sep; 20(3):455-68. PubMed ID: 17707833
[TBL] [Abstract][Full Text] [Related]
16. Initial experience with dynamic MR imaging in evaluation of normal bone marrow versus malignant bone marrow infiltrations in humans.
Bollow M; Knauf W; Korfel A; Taupitz M; Schilling A; Wolf KJ; Hamm B
J Magn Reson Imaging; 1997; 7(1):241-50. PubMed ID: 9039623
[TBL] [Abstract][Full Text] [Related]
17. Hyperdiploidy as a rare event that accompanies poor prognosis markers in CLL.
González-Gascón Y Marín I; Martín AÁ; Hernández-Sanchez M; Robledo C; Hermosín ML; de Las Heras N; Lacalle L; Galende J; de Arriba F; Rodríguez-Vicente AE; Hernández JÁ; Hernández-Rivas JM
Eur J Haematol; 2017 Feb; 98(2):142-148. PubMed ID: 27717146
[TBL] [Abstract][Full Text] [Related]
18. CD11c expression in chronic lymphocytic leukemia revisited, related with complications and survival.
Umit EG; Baysal M; Durmus Y; Demir AM
Int J Lab Hematol; 2017 Oct; 39(5):552-556. PubMed ID: 28603911
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia.
Molica S; Vitelli G; Cutrona G; Todoerti K; Mirabelli R; Digiesi G; Giannarelli D; Sperduti I; Molica M; Gentile M; Morabito F; Neri A; Ferrarini M
Int J Hematol; 2008 Nov; 88(4):374-380. PubMed ID: 18818986
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia.
Chen J; McMillan NA
Cancer Biol Ther; 2008 Feb; 7(2):174-9. PubMed ID: 18059180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
